Downloads from IHEM 2022
Tagungsbericht IHEM 2022Meeting Report IHEM 2022
Talks from IHEM 2022
Responsible for the content of the presentations is the respective speaker. No part of this publication may be reproduced without expressed written permission of the respective author or speaker, in any way reproduced or electronically processed, copied or distributed. The use of lectures and files is permitted only for the purpose of training and for personal use.
- SESSION 1: MOLECULAR – MPN PATHOGENESIS
CHAIRS: A. Mullaly & M. Doubek - A. Fleischman
Clonal evolution - R. Skoda
Risk stratification - SESSION 2: ET
CHAIRS: T. Barbui & J. Schwarz - A. Alvarez-Larrán
Unmet need in ET - R. Kušec
How I treat - M. Krauth
Patient case IFN in ET - SESSION 3: EARLY INTERVENTION IN PV – AIMING FOR DISEASE MODIFICATION
CHAIRS: J. J Kiladjian & H. Gisslinger - A. Mullaly
Pre-clinical aspects - T. Barbuih
IFN guidelines - M. Griesshammer
Practical considerations - SESSION 4: PATIENT CASES
CHAIRS: V. Buxhofer-Ausch & A. Hatalová - P. Schaffhausen
Ropeg for low risk PV – Academic question or reality - S. Papageorgiou
Pre-treated PV - M. Egyed
CHIP patient - T. Sliwa
Switch patient case - H. Gisslinger
Combination therapy - J. Göthert
Efficacy of interferon in PV - A matter of dose? - SESSION 5: CML – SET THE SCENE
CHAIRS: A. Burchert & J. Góra-Tybor - F. Stegelmann
TKIs – A backbone with limitations - A. Burchert
IFN in CML – A critical review - SESSION 7: OTHER MPN
CHAIRS: D. Wolf & M. Egyed - H. Gisslinger
Pre-PMF Where are we heading to? - V. Buxhofer-Ausch
Pre-PMF patient cases - MF. Passamonti
MF – How I treat - D. Wolf
Secondary AML - J.J Kiladjian
New compounds